Abstract
4/2025
vol. 41
Review paper
The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review
- Department of Forensic Medicine, Pomeranian Medical University, Szczecin, Poland
- Clinical Department of General Surgery, Pomeranian Medical University, Szczecin, Poland
- Clinic of Nephrology, Transplantology and Internal Diseases, University Clinical Hospital No. 2, Pomeranian Medical University, Szczecin, Poland
Medical Studies 2025; 41 (4): 322–329
Online publish date: 2025/12/15
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature. Additionally, the paper discusses the molecular biology of ADPKD and the effects of tolvaptan use on liver and kidney function, and presents the treatment of the described disease in adults and children. Complications of tolvaptan treatment are also briefly discussed.
Keywords
olycystic kidney disease, autosomal dominant inheritance, tolvaptan, treatment, autosomal dominant polycystic kidney disease
Coverage in
Integrated with
